On Sept. 1, 2020, Atossa Therapeutics announced a positive interim safety assessment from the first cohort of healthy participants in the Phase 1 clinical study using Atossaﾒs proprietary drug candidate AT-301 administered by nasal spray. This first group of 8 participants received a single dose of either AT-301A (placebo) or AT-301B (active drug). This blinded, positive assessment by the safety committee allowed the study to now enroll the next cohort.